

Pharmacokinetic (PK) Bridging ELISA

PK - Durvalumab

For Use with Anti-Durvalumab Monoclonal Antibodies catalog #TZA004 and #HCA360

This method provides a procedure for carrying out a PK ELISA with Anti-Durvalumab Antibodies, #TZA004 (capture antibody), and HRP conjugated #HCA360 (detection antibody), and using durvalumab for the standard curve. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.

Reagents

BSA
HISPEC Assay Diluent (#BUF049)
Human Serum (Sigma-Aldrich, #H4522)
LYNX Rapid HRP Antibody Conjugation Kit (#LNK001P-LNK006P)
PBS
136 mM NaCl
2.68 mM KCl
8.1 mM Na₂HPO₄
1.46 mM KH₂PO₄
PBST
PBS with 0.05% Tween 20
QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, #15169)

Materials

384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, #460518)
Fluorescence plate reader

96-well plates can be used instead of 384-well plates, black, flat-bottom wells for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, #437111). For the 96-well format, use 100 µl (instead of 20 µl) of antigen, antibodies, or substrate and 300 µl for the blocking step.

Method

1. Prepare the detection antibody: conjugate #HCA360 (AbD41313ia) using a LYNX Rapid HRP Antibody Conjugation Kit.
2. Prepare the capture Anti-Durvalumab Antibody #TZA004 (AbD41327) at 1 µg/ml in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µl per well of the prepared capture antibody, and incubate overnight at 4°C.
3. Wash the microtiter plate five times (5x) with PBST.
4. Block the microtiter plate by adding 100 µl 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
5. Wash the microtiter plate 5x with PBST.
6. For the standard curve, prepare a dilution series of durvalumabin 10% human serum in PBST in triplicate. Final concentration of durvalumab should cover the range from 0.1 ng/ml to 16,000 ng/ml. Include a zero durvalumab concentration as the background value.
7. Add 20 µl of durvalumab dilution per well (in triplicate for each standard recommended). Add 20 µl of each test sample to the other wells (in triplicate for each sample recommended). Incubate for 1 hr at RT.
8. Wash the microtiter plate 5x with PBST.
9. To each well, add 20 µl HRP conjugated detection Anti-Durvalumab Antibody, #HCA360 (AbD41313ia), at 0.5 µg/ml in HISPEC Assay Diluent. Incubate for 1 hr at RT.
10. Wash the microtiter plate 10x with PBST.
11. Add 20 µl QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc.
LYNX RAPID CONJUGATION KIT is a trademark of Bio-Rad Europe, GmbH.
All trademarks used herein are the property of their respective owner.



Bio-Rad
Laboratories, Inc.

Life Science
Group

Web site bio-rad-antibodies.com

